Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 88 of 6351
-
New CAR-T therapy targets tough T-Cell cancers in early trial
Disease control Recruiting nowTo observe the safety and efficacy of Nanobody-Based CD5-targeted chimeric antigen receptor T cells in the treatment of refractory or relapsed T-ALL/NHL
Phase 1/2 • Sponsor: Peking University People's Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
ER-to-Home plan aims to slash opioid overdose deaths
Disease control Recruiting nowOpioid overdose deaths have reached historically high records in the United States and are particularly concentrated among patients after emergency department (ED) discharge. Evidence-based treatment modules to reduce repeat opioid overdose and mortality are lacking in this patie…
Phase 1/2 • Sponsor: University of Alabama at Birmingham • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
Could a pill replace chemo for advanced breast cancer? new trial aims to find out.
Disease control Recruiting nowThe DIAMOND study (DIAMOND-01) is a multicenter, randomized, open-label, non-inferiority Phase III clinical trial conducted by Fudan University Shanghai Cancer Center. The study aims to evaluate the efficacy and safety of an oral, "non-intravenous" regimen (pyrotinib + trastuzuma…
Phase 3 • Sponsor: Fudan University • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New hope for Hard-to-Treat ovarian cancer: Rina-S faces off against standard chemo in major trial
Disease control OngoingThis phase 3 study will be conducted in different countries all over the world. The purpose of this study is to compare how well Rina-S works against platinum-resistant ovarian cancer compared to chemotherapy drugs that are already approved and used for platinum-resistant ovaria…
Phase 3 • Sponsor: Genmab • Aim: Disease control
Last updated Sep 10, 2026 01:00 UTC
-
Could a pill help stop breast cancer from spreading after a local return?
Disease control Recruiting nowThe JCOG2313 trial is a multicenter, randomized, phase III study designed to evaluate the efficacy and safety of adjuvant abemaciclib in combination with endocrine therapy versus endocrine therapy alone in patients with hormone receptor (HR)-positive, HER2-negative breast cancer …
Phase 3 • Sponsor: Japanese Foundation for Cancer Research • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
Your gut bacteria might reveal hidden cancer risk
Diagnosis Recruiting nowColorectal cancer (CRC) is one of the most common cancer and cause of cancer death worldwide. Population-based screening programs for average risk populations have proven effective in reducing both incidence and mortality of CRC through early detection of cancer. The fecal immuno…
Sponsor: Catholic University of the Sacred Heart • Aim: Diagnosis
Last updated Aug 15, 2026 00:00 UTC
-
Custom Gene-Targeting drug offers hope for one child with fatal brain disorder
Disease control OngoingThis research project entails delivery of a personalized antisense oligonucleotide (ASO) drug designed for a single participant with Childhood-Onset Neurodegeneration with Brain Atrophy (CONDBA) due to a heterozygous missense gain-of-function mutation in UBTF
Phase 1/2 • Sponsor: n-Lorem Foundation • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
Could buntanetap slow Alzheimer's? major trial underway
Disease control OngoingThe goal of this clinical trial is to learn if buntanetap/Posiphen works to treat early Alzheimer's disease in adults aged 55-85. It will also learn about the safety of buntanetap/Posiphen. The main questions it aims to answer are: * Does buntanetap/Posiphen improve cognition as…
Phase 3 • Sponsor: Annovis Bio Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
Brain cancer patients get new hope: electric fields plus immunotherapy tested in major trial
Disease control Recruiting nowThis is a multicenter, two-arm, randomized, double-blind, placebo-controlled study of Optune® (Tumor Treating Fields at 200 kHz) together with maintenance Temozolomide (TMZ) chemotherapy agent and pembrolizumab compared to Optune® together with maintenance TMZ and placebo in newl…
Phase 3 • Sponsor: NovoCure GmbH • Aim: Disease control
Last updated Aug 21, 2026 00:00 UTC
-
New drug could shield preemie lungs from deadly disease
Prevention Recruiting nowThis is a randomized, parallel-group, double-blind, placebo-controlled multicenter phase 2b/3 study with an adaptive seamless design. The goal fo this study is to determine if an investigational drug, Zelpultide Alfa, can reduce the occurrence of Bronchopulmonary Dysplasia (BPD)…
Phase 2/3 • Sponsor: Airway Therapeutics, Inc. • Aim: Prevention
Last updated Jul 17, 2026 00:00 UTC
-
New hope for aggressive lung cancer: phase 3 trial launches
Disease control Recruiting nowThis is a Phase III, multisite, randomized, double-blinded study to investigate pumitamig (BNT327) combined with chemotherapy (etoposide/carboplatin) compared to atezolizumab combined with chemotherapy (etoposide/carboplatin) for the treatment of participants with previously untr…
Phase 3 • Sponsor: BioNTech SE • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
Engineered immune cells take on Hard-to-Treat myeloma
Disease control Recruiting nowThe mail purpose of this study is to estimate the safety and the efficacy of anti-BCMA CAR- T cell immunotherapy for adults with relapsed or refractory multiple myeloma
Phase 1/2 • Sponsor: Minsk Scientific-Practical Center for Surgery, Transplantation and Hematology • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
Promising combo therapy for aggressive brain cancer enters final testing phase
Disease control Recruiting nowBackground: Glioblastoma (GBM) is notoriously difficult to treat, with current therapies often extending life by only a few months. The standard treatment involves surgery followed by radiation and chemotherapy with Temozolomide (TMZ). The efficacy of TMZ, however, is significant…
Phase 3 • Sponsor: Vastra Gotaland Region • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
Donor immune cells take on tough T-Cell cancers in new trial
Disease control Recruiting nowThe T-RRex study evaluates the efficacy of WU-CART-007 for patients with Relapsed/Refractory (R/R) T-Cell Acute Lymphoblastic Leukemia (T-ALL)/Lymphoblastic Lymphoma (LBL) and to WU-CART-007 as a therapy to induce complete Minimum Residual Disease (MRD) negative response
Phase 2 • Sponsor: Allotera Therapeutics • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
Engineered immune cells take on childhood cancer in new trial
Disease control Recruiting nowThis Phase 1/2 trial aims to determine the safety and feasibility of administration of autologous chimeric antigen receptor (CAR) T cells targeting the human Anaplastic Lymphoma Kinase (ALK) receptor in pediatric subjects with relapsed or refractory neuroblastoma (NB). The trial…
Phase 1/2 • Sponsor: Roberto Chiarle • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
New lung cancer drug aims to match Keytruda's success
Disease control OngoingThe goal of this Phase 3 clinical trial is to compare efficacy and safety of CT-P51 and European Union (EU) approved Keytruda in combination with platinum pemetrexed chemotherapy in patients with previously untreated metastatic nsNSCLC.
Phase 3 • Sponsor: Celltrion • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
Triple-Drug attack aims to stop mantle cell lymphoma without chemo
Disease control OngoingPrimary Objectives: To estimate the percent of participants who achieve a best response of complete response by the end of the PRV combination therapy in the induction therapy phase in patients with previously untreated MCL.
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Ancient herb, modern hope: ashwagandha compound tested to prevent deadly transplant complication
Disease control Recruiting nowWhat is acute Graft versus host disease (aGvHD)? GvHD is a complication that can occur after an allogeneic stem cell transplant resulting in damage to some organs. The death rate of GvHD patients is 15-40%. In GvHD, the donated peripheral blood stem cells or bone marrow view the …
Phase 1/2 • Sponsor: Tata Memorial Centre • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC
-
Could a diabetes drug curb opioid addiction? a trial puts semaglutide to the test
Disease control Recruiting nowThe goal of this clinical trial is to learn if semaglutide can reduce illicit opioid use in adults in outpatient treatment for opioid use disorder, and who are receiving either buprenorphine or methadone maintenance treatment. The main question it aims to answer is: • Does semag…
Phase 2 • Sponsor: Milton S. Hershey Medical Center • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
AI eyes hidden heart condition: could algorithms catch what doctors miss?
Diagnosis OngoingThis is a multi-center, observational study with the overall objective to examine the scale of under-diagnosis for transthyretin amyloid cardiomyopathy (ATTR-CM) across a broad range of diverse health systems in the US using a fully federated deployment of an artificial intellige…
Sponsor: Yale University • Aim: Diagnosis
Last updated Jul 31, 2026 00:00 UTC